Fmoc-Glu-OAll

Fmoc-Glu-OAll is an orthogonal building block specifically designed for the synthesis of head‑to‑tail cyclic peptides and complex peptide architectures via Fmoc SPPS. The α‑allyl ester of Fmoc-Glu-OAll can be selectively removed in the presence of Fmoc‑ and tBu‑based protecting groups by treatment with Pd(Ph₃P)₄ in CHCl₃/AcOH/NMM, making Fmoc-Glu-OAll an indispensable tool for preparing cyclic peptides where a glutamyl residue is positioned at the cyclization junction. After solid‑phase linear assembly, the allyl ester is cleaved with Pd(0), the N‑terminal Fmoc is removed, and cyclization is performed between the newly freed α‑amine and the freed α‑carboxyl — all while side‑chain protecting groups (including the free γ‑carboxyl) remain intact. Fmoc-Glu-OAll also facilitates the synthesis of branched esters and amides, lactones, and lactams incorporating a glutamyl unit, demonstrating the remarkable synthetic versatility of this orthogonal building block. With a well‑defined melting point (118–122 °C), high enantiomeric purity (≥99.5% a/a), and broad availability at research to commercial scales, Fmoc-Glu-OAll continues to be the building block of choice for chemists constructing cyclic peptide therapeutics, side‑chain modified glutamyl peptides, and complex branched architectures in both academic and industrial settings.

Product Parameters

Why Cosperpharm?

Your cyclic peptide synthesis campaign — whether targeting head‑to‑tail cyclized drug candidates, branched glutamyl peptides, or complex lactam‑containing scaffolds — requires orthogonal building blocks you can rely on. Cosperpharm delivers Fmoc-Glu-OAll with the analytical rigor, documentation depth, and supply flexibility that peptide chemists and pharmaceutical manufacturers demand.

Orthogonal protection validated on every batch. The Fmoc/allyl orthogonal protection scheme of Fmoc-Glu-OAll is the critical success factor for head‑to‑tail cyclization strategies. Any impurity — free Fmoc‑glutamic acid, residual allyl alcohol, dipeptide formation, or enantiomeric contamination — will compromise selective deprotection and cyclization efficiency. Our analytical release protocol includes HPLC purity verification (≥98.0%; ≥99.0% for Novabiochem® grade), optical rotation confirmation ([α]²⁰/D −17.0 to −21.0°), enantiomeric purity verification (≥99.5% a/a), melting point determination (118–122 °C), water content (Karl Fischer ≤ 1.0%), and identity confirmation by IR.

Documentation that supports regulatory and GMP submissions. Every shipment of Fmoc-Glu-OAll includes a Certificate of Analysis (COA) with batch‑specific purity data, chromatographic traceability, enantiomeric purity, and residual solvent analysis — structured for direct insertion into your method validation or GMP documentation package. DMF‑ready documentation, stability summaries, and custom quality agreements are available upon request for customers incorporating this building block into commercial peptide API manufacturing.

Flexible supply across all development stages. Cosperpharm supplies Fmoc-Glu-OAll across the full range of applications — from 1g–50g quantities for academic cyclic peptide research and method development, to 100g–500g batches for process validation and pilot‑scale synthesis, to 1kg–25kg drums for commercial peptide API manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

Technical support for your entire synthetic workflow. Our process chemistry team can advise on selective Pd(0)‑mediated allyl ester cleavage conditions, compatibility with other orthogonal protecting groups (tBu, Boc, Trt, Alloc), and analytical methods for detecting process‑related impurities and cyclization byproducts — because we have worked extensively with this orthogonal building block across multiple cyclic peptide manufacturing campaigns.

Global reach with transparent pricing. Cosperpharm ships to peptide manufacturers, CDMOs, CROs, and academic research laboratories worldwide, with full customs documentation included. Volume discounts apply at kilogram scales, and we communicate lead times upfront — no hidden fees, no unexpected delays.

Storage Conditions

Store Fmoc-Glu-OAll in a tightly sealed container, preferably under inert atmosphere (nitrogen or argon), at –20 °C for long‑term storage or at 2–8 °C for short‑term storage. Keep the container dry and protected from light. The compound is stable under recommended storage conditions; avoid exposure to moisture, strong bases (which may cleave the Fmoc group), strong oxidizing agents, and palladium scavengers. Allow the sealed container to reach ambient temperature before opening to minimize moisture condensation.

Shelf life: 3 years when stored at –20 °C in a sealed container under inert atmosphere; 2 years when stored at 4 °C. Accelerated stability data and long‑term stability summaries are available upon request to support regulatory filings.

Handling precautions: Use only in a fume hood. Wear chemical‑resistant gloves (tested against EN 374 or equivalent), safety goggles, and a lab coat. Avoid generating dust or aerosols. Do not eat, drink or smoke in work areas. After handling, wash hands thoroughly. Refer to the Safety Data Sheet (SDS) for complete safety information.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Fmoc-Glu-OAll that meets the rigorous expectations of both research peptide synthesis and GMP cyclic peptide manufacturing:

Thorough analytical characterization. Each batch of Fmoc-Glu-OAll undergoes multi‑technique analytical release testing: HPLC purity verification (≥98.0%; ≥99.0% for Novabiochem® grade with full chromatographic traceability), enantiomeric purity determination (≥99.5% a/a by chiral HPLC or optical rotation), melting point verification (118–122 °C), appearance verification (white to off‑white powder), water content determination (Karl Fischer ≤ 1.0%), residual solvent analysis (GC), identity confirmation (IR), and where applicable, ¹H NMR and MS confirmation of molecular identity.

Full batch traceability with retention samples. From raw material procurement (Fmoc‑OSu or Fmoc‑Cl, L‑glutamic acid, allyl alcohol from qualified suppliers) through selective α‑esterification, Fmoc protection, purification, crystallization, drying, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions: long‑term storage at –20 °C under inert atmosphere, with accelerated stability studies (40 °C / 75% RH) conducted on representative batches. Stability summaries are updated regularly, with full data packages available to support customer regulatory submissions. Shelf life: 3 years at –20 °C; 2 years at 4 °C.

Documentation ready for regulatory submission. Every shipment of Fmoc-Glu-OAll includes a Certificate of Analysis (COA) with batch‑specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers preparing ANDA or NDA filings for cyclic peptide therapeutics, Cosperpharm provides DMF‑ready documentation packages, method validation reports, stability data, and custom quality agreements upon request. Traceability against reference standards can be provided based on feasibility.

Customer‑initiated quality audits. Qualified customers are welcome to audit Cosperpharm‘s manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit. ISO compliance documentation is available upon request.

Contact us

From early‑stage cyclic peptide discovery to commercial GMP production, having a reliable source of high‑purity Fmoc-Glu-OAll makes all the difference. Cosperpharm provides the orthogonal building blocks you need — with the analytical documentation, flexible scaling, and technical support to back it up. Reach out today to discuss your project requirements or to request a quote.